• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment on: "Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta‑analysis".

作者信息

Ma Jun, Han Wei

机构信息

Department of Urology Surgery, Kunshan Hospital of Traditional Chinese Medicine, Kunshan, 215300, Jiangsu, People's Republic of China.

Department of General Surgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, 215300, Jiangsu, People's Republic of China.

出版信息

Target Oncol. 2024 Sep;19(5):811-812. doi: 10.1007/s11523-024-01082-9. Epub 2024 Jul 19.

DOI:10.1007/s11523-024-01082-9
PMID:39028408
Abstract
摘要

相似文献

1
Comment on: "Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta‑analysis".对《PARP抑制剂在携带BRCA或HRR基因突变的转移性前列腺癌患者中的血液学毒性：系统评价与安全性Meta分析》的评论
Target Oncol. 2024 Sep;19(5):811-812. doi: 10.1007/s11523-024-01082-9. Epub 2024 Jul 19.
2
Author's Reply to Ma et al.: "Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis".作者对马等人的回复：“PARP抑制剂对携带BRCA或HRR基因突变的转移性前列腺癌患者的血液学毒性：一项系统评价和安全性荟萃分析”
Target Oncol. 2024 Sep;19(5):813-815. doi: 10.1007/s11523-024-01083-8. Epub 2024 Jul 19.
3
BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations.BRCA 基因突变与前列腺癌：评估、影响及治疗策略考量。
Int J Mol Sci. 2021 Nov 23;22(23):12628. doi: 10.3390/ijms222312628.
4
PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.聚腺苷二磷酸核糖聚合酶抑制剂与前列腺癌：超越 BRCA。
Oncologist. 2021 Jan;26(1):e115-e129. doi: 10.1634/theoncologist.2020-0697. Epub 2020 Sep 8.
5
PARP Inhibitors in Prostate Cancer.聚腺苷二磷酸核糖聚合酶抑制剂在前列腺癌中的应用。
Anticancer Res. 2021 Feb;41(2):551-556. doi: 10.21873/anticanres.14807.
6
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.同时存在 BRCA2/SPOP 突变可预测转移性去势抵抗性前列腺癌对聚（ADP-核糖）聚合酶抑制剂的敏感性。
Eur Urol Oncol. 2024 Aug;7(4):877-887. doi: 10.1016/j.euo.2023.11.014. Epub 2023 Dec 9.
7
A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR).鲁卡帕尼单药治疗非转移性、激素敏感性前列腺癌的II期研究，显示“BRCA样”基因型（ROAR）。
Oncologist. 2024 May 3;29(5):450-e725. doi: 10.1093/oncolo/oyae030.
8
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of Reversion Mutations Associated with Resistance to PARP Inhibitors.循环无细胞 DNA 分析鉴定与 PARP 抑制剂耐药相关的回复突变的多克隆异质性。
Cancer Discov. 2017 Sep;7(9):999-1005. doi: 10.1158/2159-8290.CD-17-0146. Epub 2017 Apr 27.
9
Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.多聚 BRCA2 突变继发于卡铂治疗后，导致 mCRPC 患者对 PARP 抑制剂芦卡帕利产生耐药：病例报告。
BMC Cancer. 2020 Mar 14;20(1):215. doi: 10.1186/s12885-020-6657-2.
10
TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations.TRIUMPH 研究：聚乙二醇化重组人粒细胞刺激因子在接受含铂化疗的晚期非小细胞肺癌患者中的应用
Oncologist. 2024 Sep 6;29(9):794-800. doi: 10.1093/oncolo/oyae120.

本文引用的文献

1
Safety and efficacy of Cox-Maze procedure for atrial fibrillation during mitral valve surgery: a meta-analysis of randomized controlled trials.经导管二尖瓣缘对缘修复术治疗二尖瓣关闭不全伴心房颤动的疗效及安全性：一项 Meta 分析。
J Cardiothorac Surg. 2024 Mar 19;19(1):140. doi: 10.1186/s13019-024-02622-0.
2
Confidence intervals for validation statistics with data truncation in genomic prediction.截断数据下基因组预测中验证统计量的置信区间。
Genet Sel Evol. 2024 Mar 8;56(1):18. doi: 10.1186/s12711-024-00883-w.
3
Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis.
PARP 抑制剂在携带有 BRCA 或 HRR 基因突变的转移性前列腺癌患者中的血液学毒性：系统评价和安全性荟萃分析。
Target Oncol. 2024 Jan;19(1):1-11. doi: 10.1007/s11523-023-01016-x. Epub 2023 Nov 22.
4
Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of Lu-PSMA I&T.接受连续 Lu-PSMA I&T 治疗的转移性去势抵抗性前列腺癌患者的生活质量得到改善。
J Nucl Med. 2023 Nov;64(11):1765-1771. doi: 10.2967/jnumed.123.265878. Epub 2023 Sep 7.
5
The nuts and bolts of PROSPERO: an international prospective register of systematic reviews.PROSPERO 的要点：一个国际性的系统综述前瞻性注册库。
Syst Rev. 2012 Feb 9;1:2. doi: 10.1186/2046-4053-1-2.